{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:32:20Z","timestamp":1770755540072,"version":"3.50.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24H02634"],"award-info":[{"award-number":["JP24H02634"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jiac.2025.102654","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:11:20Z","timestamp":1738915880000},"page":"102654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of doses based on body constitutional parameters with the efficacy of micafungin in candidemia"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1487-5231","authenticated-orcid":false,"given":"Masaya","family":"Nagamizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-7775","authenticated-orcid":false,"given":"Yuji","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-7471","authenticated-orcid":false,"given":"Daigaku","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-0000","authenticated-orcid":false,"given":"Yuto","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1191-8792","authenticated-orcid":false,"given":"Yasuhiro","family":"Horita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Furukawa\u2013Hibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102654_bib1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00134-014-3400-y","article-title":"Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period","volume":"40","author":"Colombo","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2025.102654_bib2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00134-014-3408-3","article-title":"Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)","volume":"40","author":"Lortholary","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2025.102654_bib3","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1128\/JCM.01998-13","article-title":"Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain","volume":"51","author":"Bassetti","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jiac.2025.102654_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13613-015-0103-7","article-title":"Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study","volume":"6","author":"Leroy","year":"2016","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jiac.2025.102654_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chest.2021.08.081","article-title":"Risk factors for invasive Candida infection in critically ill patients: a systematic review and meta-analysis","volume":"161","author":"Thomas-R\u00fcddel","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2025.102654_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13054-016-1313-6","article-title":"Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy","volume":"20","author":"Calandra","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2025.102654_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.jiac.2025.102654_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID\u2217 guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2025.102654_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102654_bib14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10096-004-1228-z","article-title":"Pharmacokinetics\/pharmacodynamics of echinocandins","volume":"23","author":"Theuretzbacher","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","article-title":"Population pharmacokinetic model and pharmacokinetic target attainment of micafungin in intensive care unit patients","volume":"56","author":"Martial","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2025.102654_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14787210.2016.1128822","article-title":"Dosing of antifungal agents in obese people","volume":"14","author":"Payne","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiac.2025.102654_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01398-17","article-title":"Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis","volume":"61","author":"Boonstra","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"10.1016\/j.jiac.2025.102654_bib18","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib19","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2147\/IDR.S274872","article-title":"Candidemia: evolution of drug resistance and novel therapeutic approaches","volume":"14","author":"Tortorano","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2025.102654_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vhri.2019.07.002","article-title":"The economic burden of candidemia and invasive candidiasis: a systematic review","volume":"21","author":"Wan","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jiac.2025.102654_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091145","article-title":"Evaluation of population pharmacokinetic models of micafungin: implications for dosing regimen optimization in critically ill patients","volume":"16","author":"Li","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102654_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02307-20","article-title":"Prospective cohort study of micafungin population pharmacokinetic analysis in plasma and peritoneal fluid in septic patients with intra-abdominal infections","volume":"65","author":"Garbez","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16060819","article-title":"Development and quality control of a population pharmacokinetic model library for caspofungin","volume":"16","author":"Xu","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102654_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00248-19","article-title":"Body surface area-based dosing regimen of caspofungin in children: a population pharmacokinetics confirmatory study","volume":"63","author":"Yang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2025.102654_bib27","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known","volume":"5","author":"Du Bois","year":"1916","journal-title":"Nutrition"},{"key":"10.1016\/j.jiac.2025.102654_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1067\/mcp.2002.129306","article-title":"Caution when lean body weight is used as a size descriptor for obese subjects","volume":"72","author":"Bruce Green","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2025.102654_bib29","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","year":"2017"},{"key":"10.1016\/j.jiac.2025.102654_bib30","article-title":"Executive summary of Japanese domestic guidelines for management of deep-seated mycosis 2014","volume":"57","author":"Kohno","year":"2016","journal-title":"Med Mycol J"},{"key":"10.1016\/j.jiac.2025.102654_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102654_bib32","series-title":"Performance standards for antifungal susceptibility testing of yeasts","year":"2022"},{"key":"10.1016\/j.jiac.2025.102654_bib33","article-title":"Treatment of invasive candidiasis: a narrative review","volume":"4","author":"Ben-Ami","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jiac.2025.102654_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","article-title":"Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study","volume":"23","author":"Hoenigl","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2025.102654_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40121-020-00285-7","article-title":"Impact of obesity in patients with Candida bloodstream infections: a retrospective cohort study","volume":"9","author":"Barber","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102654_bib37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jiac.2025.102654_bib38","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10156-007-0522-Y","article-title":"Relationship between the initial dose of micafungin and its efficacy in patients with candidemia","volume":"13","author":"Ota","year":"2007","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00228-020-02840-0","article-title":"Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations","volume":"76","author":"Lu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102654_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","article-title":"Population pharmacokinetics of micafungin in adult patients","volume":"60","author":"Gumbo","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib43","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","author":"Hall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106614","article-title":"Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses","volume":"60","author":"Domingos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102654_bib45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11046-020-00471-8","article-title":"Anidulafungin versus micafungin in the treatment of candidemia in adult patients","volume":"185","author":"Suh","year":"2020","journal-title":"Mycopathologia"},{"key":"10.1016\/j.jiac.2025.102654_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jmii.2013.09.006","article-title":"Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia","volume":"47","author":"Lee","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2025.102654_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/myc.12748","article-title":"Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia","volume":"61","author":"Chandrasekar","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2025.102654_bib48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12879-016-1825-3","article-title":"Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study","volume":"16","author":"van der Geest","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2025.102654_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/myc.13060","article-title":"Treatment of invasive fungal infections in intensive care units with micafungin: the MYRIADE study","volume":"63","author":"Timsit","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2025.102654_bib50","series-title":"Guidelines for the management of obesity disease 2016","author":"JsftSo","year":"2016"},{"key":"10.1016\/j.jiac.2025.102654_bib51","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \"sepsis-related problems\" of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102654_bib52","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/AAC.00478-08","article-title":"In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib53","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib54","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1128\/AAC.04474-14","article-title":"In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies","volume":"59","author":"Gil-Alonso","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib55","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/AAC.01538-09","article-title":"In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies","volume":"54","author":"Cant\u00f3n","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102654_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myac071","article-title":"Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010-2019: a retrospective observational study based on national surveillance data","volume":"60","author":"Kajihara","year":"2022","journal-title":"Med Mycol"},{"key":"10.1016\/j.jiac.2025.102654_bib57","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","article-title":"A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:16:20Z","timestamp":1744424180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1341321X25000510"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102654","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of doses based on body constitutional parameters with the efficacy of micafungin in candidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102654"}}